There were no major surprises within
North American sales growth eclipsed both European and APAC region growth, explains the analyst. Unfortunately, Europe accounts for 54.2% of revenue and is considered a key driver for SomnoMed due to a more favourable reimbursement environment.
The broker suggests recent share price weakness is a long-term buying opportunity.
The Add rating and
Sector: Health Care Equipment & Services.
Target price is
© 2023 Acquisdata Pty Ltd., source